However, our study is the first to reveal that sitagliptin induces cardioprotective effects, at least in part, through modulation of the mTOR–VEGF–FLT-1 axis in diabetic cardiomyopathy. The gene discussed is FLT1; the disease is diabetic cardiomyopathy.